Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2021

View Archived Issues

Enrollment ongoing in phase I/II study of PVSRIPO

Mersana starts phase I/II umbrella study of XMT-1536 in high-grade serous ovarian cancer

Venadaparib shows safety and preliminary efficacy in first-in-human trial

Novel tau tubulin kinase 1 inhibitors reduce tau phosphorylation in vivo

Vaccinia virus-expressed SARS-CoV-2 spike protein promotes cellular and humoral immunity in mice

Antitumor activity of luxeptinib described in phase Ia/b study in B-cell malignancies

BCMA CAR-T cells engineered with membrane-bound IL-15 show increased in vivo activity

Dose-dependent weight loss seen in first-in-human study of LY-3437943

Model of diastolic dysfunction with preserved ejection fraction developed to test HDAC6 inhibition

Phase I data for CC-90001 in healthy subjects and in participants with hepatic impairment

Roche patents new BRAF inhibitors

Chinese investigators divulge P2X3 receptor antagonists

Shenzhen Jingtai Technology presents Ret inhibitors

Vivavision Biotechnology describes new ROCK2 inhibitors

PTC Therapeutics discloses compounds for familial dysautonomia

SYNB-1934, optimized live bacterial therapeutic for the treatment of phenylketonuria

Bio-ADM, a novel biomarker of congestion in acute dyspnea

Phase II FORCE study of avdoralimab in COVID-19 misses primary endpoints

Phase I/II trial explores Gadeta's gamma delta TCR cell therapy GDT-002 for multiple myeloma

Downregulation of ERBB4 leads to peripartum cardiomyopathy

HUTCHMED initiates phase I study of HMPL-295 in advanced solid tumors

HIV rebound biomarkers give insights into controllers and, unexpectedly, comorbidities

BNC-210 advances into phase IIb trial in PTSD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...